Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Stellar Biotechnologies Inc. (NASDAQ: SBOT).

Full DD Report for SBOT

You must become a subscriber to view this report.


Recent News from (NASDAQ: SBOT)

Stellar Biotechnologies to Present at BlueTech Summit
LOS ANGELES , Oct. 31, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, announced today that Stellar President and CEO Frank R. Oakes will present...
Source: PR Newswire
Date: October, 31 2018 07:30
Midday Gainers / Losers (09/05/2018)
Gainers: PRQR +62% . MNKD +33% . SBOT +19% . VCEL +18% . NSU +17% . SYBX +15% . CORV +15% . VRA +15% . MVIS +14% . IGC +13% . More news on: ProQR Therapeutics, MannKind Corporation, Stellar Biotechnologies Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 05 2018 12:47
Stellar Biotech up 11% on NIH contract for KLH
Nano cap Stellar Biotechnologies ( SBOT +11.4% ) is up on more than triple normal volume in response to its announcement of a contract with the U.S. National Institutes of Health (NIH) to supply its Stellar KLH protein for clinical studies. More news on: Stellar Biotechnologies Inc., H...
Source: SeekingAlpha
Date: September, 05 2018 11:08
Premarket Gainers as of 9:05 am (09/05/2018)
PRQR +66%  on positive interim results from Phase 1/2 clinical trial of QR-110 in LCA10 patients. More news on: ProQR Therapeutics, Cronos Group, Inc., Nevsun Resources Ltd., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 05 2018 09:21
Stellar Biotechnologies to Supply KLH to National Institutes of Health
LOS ANGELES , Sept. 5, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, autoimmune disease and cancers, among other diseases, announced today that it h...
Source: PR Newswire
Date: September, 05 2018 07:30
Stellar Biotechnologies to Present at H. C. Wainwright Global Investment Conference
LOS ANGELES , Aug. 28, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, announced today that Stellar CEO and P...
Source: PR Newswire
Date: August, 28 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-121.131.081.151.08106,398
2018-12-111.181.091.181.0897,255
2018-12-101.151.12221.171.08191,949
2018-12-071.111.141.23391.11655,435
2018-12-061.131.13071.191.10169,605

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-128,45045,61918.5230Cover
2018-12-114,04646,7938.6466Cover
2018-12-108,35545,99918.1634Cover
2018-12-07112,393210,68253.3472Short
2018-12-0632,44674,44343.5850Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SBOT.


About Stellar Biotechnologies Inc. (NASDAQ: SBOT)

Logo for Stellar Biotechnologies Inc. (NASDAQ: SBOT)

Stellar Biotechnologies, Inc. OTCQB: SBOTF TSX VENTURE: KLH is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin KLH , an important immune stimulating protein used in wide ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient API in many new immunotherapies targeting cancer, immune disorders, Alzheimer s and inflammatory diseases as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH based active immunotherapies. Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org.

 

 

 

Current Management

  • Frank Oakes / CEO, President
    • Mr. Oakes has more than years of management experience in aquaculture including a decade as CEO of The Abalone Farm, Inc., during which he led that company through the R amp D, capitalization and commercialization phases of development to become the first profitable and largest abalone producer in the U.S.. He is the inventor of the company s patented method for nonlethal extraction of hemolymph from the keyhole limpet. He was the Principal Investigator on the company s Phase I and II SBIR grants from the NIH s Center for Research Resources, NSF grant, and a California Technology Investment Partnership CalTIP grant from the Department of Commerce. He has consulted and lectured for the aquaculture industry around the world. Frank received his Bachelor of Science degree from California Polytechnic State University, San Luis Obispo and is a graduate of the Los Angeles Regional Technology Alliance LARTA University s managementtraining program.
  • Catherine Brisson, Ph.D. / COO
    • Dr. Brisson has more than years of experience in the biotechnology, pharmaceutical and medical device industries with strong expertise, and broad scientific and operational understanding, in the areas of quality assurance, quality control, regulatory affairs, manufacturing, and product development. She has extensive background in process development and in the preparation and review of regulatory submissions and subsequent maintenance as well as a strong working knowledge of global regulatory requirements. Previously, Dr. Brisson held key senior management positions with startup biotechnology companies, as well as Sicor Pharmaceuticals Teva Parenteral Products . Dr. Brisson holds a B.S. degree in Chemistry from North Carolina State University and a Ph.D. in Organic Chemistry from the University of North Carolina.
  • Kathi Niffenegger / CFO, Corporate Secretary
    • Ms. Niffenegger has more than years of experience in accounting and finance in a range of industries. She currently holds the positions of Chief Financial Officer and Corporate Secretary, having previously served as Stellar s outside CPA since the Company s founding in and Controller since . Ms. Niffenegger was previously technical partner in the audit division of Glenn Burdette CPAs, obtained CFO experience at Martin Aviation, and began her CPA career at Peat, Marwick, Mitchell amp Co. now KPMG LLP . She held leadership roles for audits of manufacturing, aquaculture, pharmaceutical, and governmental grant clients, and developed specific expertise in cost accounting systems and internal controls. Ms. Niffenegger holds a B.S. degree in Business Administration from California State University, Long Beach.
  • Mark McPartland / VP, Corp. Dev., VP, Corp. Comm.
    • Mr. McPartland has more than years of experience in business development, capital markets advisory, corporate communications and Csuite consulting. Prior to joining Stellar, he served as Senior Vice President at MZ Group, a subsidiary of titude Global, the world s largest independent global investor relations IR consulting firm, which served as Stellar s IR agency. Mr. McPartland s background includes guiding the development and execution of corporate strategy for private and public companies at all stages of commercial evolution, including early and midstage biopharmaceutical entities. His previous positions include Vice President and Partner at Alliance Advisors, LLC and Regional Vice President of Hayden Communications, Inc. Mr. McPartland holds a B.S. in Business Administration and Marketing from Coastal Carolina University.
  • Frank Oakes / Chairman
    • Mr. Oakes has more than years of management experience in aquaculture including a decade as CEO of The Abalone Farm, Inc., during which he led that company through the R amp D, capitalization and commercialization phases of development to become the first profitable and largest abalone producer in the U.S.. He is the inventor of the company s patented method for nonlethal extraction of hemolymph from the keyhole limpet. He was the Principal Investigator on the company s Phase I and II SBIR grants from the NIH s Center for Research Resources, NSF grant, and a California Technology Investment Partnership CalTIP grant from the Department of Commerce. He has consulted and lectured for the aquaculture industry around the world. Frank received his Bachelor of Science degree from California Polytechnic State University, San Luis Obispo and is a graduate of the Los Angeles Regional Technology Alliance LARTA University s managementtraining program.
  • Gregory T Baxter /
  • Tessie M. Che /
  • David Hill /
  • Daniel Morse /
  • Mayank Sampat /

Current Share Structure

  • Market Cap: $3,366,427 - 05/18/2018
  • Issue and Outstanding: 1,502,869 - 05/07/2018

 


Recent Filings from (NASDAQ: SBOT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 08 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: August, 08 2018
Prospectus filed under Rule 424(b)(4)
Filing Type: 424B4Filing Source: edgar
Filing Date: June, 18 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: June, 15 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: June, 06 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: June, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 17 2018

 

 


Daily Technical Chart for (NASDAQ: SBOT)

Daily Technical Chart for (NASDAQ: SBOT)


Stay tuned for daily updates and more on (NASDAQ: SBOT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SBOT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SBOT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SBOT and does not buy, sell, or trade any shares of SBOT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/